AstraZeneca
Compare AstraZeneca…UK-Swedish diversified pharma. AZD6234 (oral amylin agonist, APRICUS Phase 2b completing 2026) and ECC5004 (oral GLP-1) build a credible third-tier obesity franchise behind Lilly and Novo.
SectorsGLP-1
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
AstraZenecaUK-Swedish diversified pharma. AZD6234 (oral amylin agonist, APRICUS Phase 2b completing 2026) and ECC5004 (oral GLP-1) build a credible third-tier obesity franchise behind Lilly and Novo.
| Asset / Mechanism | Phase / Trial Name | Key Endpoint + Readout Window |
|---|---|---|
| AZD5004 (formerly ECC5004) Phase 1 SAD | Phase 1 SAD (single ascending dose) | Pre-licensing Eccogene readouts demonstrated dose-related pharmacokinetics + initial weight reduction signals at 28 days; supported AZN licensing decision in November 2023 |
| AZD5004 Phase 1 MAD (obesity cohort) | Phase 1 MAD; H1 2025 topline | Oral once-daily small-molecule GLP-1 RA; 4-week multiple-ascending-dose study demonstrated dose-related weight loss; positioned competitively with LLY orforglipron + GPCR aleniglipron Phase 1 data |
| AZD5004 Phase 2 obesity | Phase 2b; initiated late 2024; obesity topline expected late 2025 to early 2026 | Larger cohort + extended duration; primary endpoint weight loss at 12-26 weeks; supports Phase 3 dose selection. Competitive readout vs LLY orforglipron + GPCR aleniglipron Phase 2 data |
| AZD5004 Phase 2 T2D | Phase 2; ongoing | Parallel T2D program; HbA1c + weight loss endpoints; supports T2D label pathway alongside obesity |
| AZD5004 Phase 3 obesity registrational | Phase 3; target initiation 2027 | Pivotal Phase 3 program; target FDA approval 2029-2030; commercial launch target 2030 |
| AZD6234 Phase 1 (long-acting injectable amylin receptor agonist) | Phase 1; 2024-2025 readouts | Internal AstraZeneca asset disclosed November 2024; long-acting subcutaneous injectable amylin receptor agonist (mechanistically novel, complements GLP-1 via appetite suppression + delayed gastric emptying); well-tolerated in the Phase 1 healthy-volunteer study; advancing into its own Phase 2 obesity trial |
| AZD6234 Phase 2 obesity | Phase 2; initiated 2025 | Larger cohort obesity Phase 2; topline 2026; supports Phase 3 advancement decision |
| AZD5004 + AZD6234 combination Phase 1 | Phase 1 combination; 2025-2026 | Combination dosing study evaluating oral GLP-1 (AZD5004) + injectable amylin (AZD6234); the strategic differentiation is a GLP-1 + amylin combination, analogous in mechanism to NVO CagriSema (a two-injectable peptide combo) but pairing an oral GLP-1 with an injectable amylin. Mechanistic synergy hypothesis: GLP-1 + amylin complementary satiety pathways |
| Eccogene in-licensing deal economics | Signed November 2023 | Total deal value up to ~$2B: $185M upfront + $1.825B in milestones + royalties on commercial sales. AZN took global rights ex-China; Eccogene retains Greater China. AstraZeneca's licensing approach is smaller + more-targeted than Roche's $2.7B Carmot acquisition, reflecting AZN's smaller obesity-budget allocation |
| Editorial. Why AZN matters | Strategic context | AZN's GLP-1 + amylin combination strategy is the most-differentiated approach among Big Pharma late entrants. The oral GLP-1 race is crowded (LLY, GPCR, RHHBY, AZN, others), but AZN is the only one running a parallel oral amylin program with combination intent. If AZD5004 + AZD6234 combination Phase 1 demonstrates synergistic weight loss without prohibitive GI burden, AZN has a unique product positioning. If the combination is no better than GLP-1 monotherapy, AZN is a fast-follower in the crowded oral GLP-1 race |
| Deal / Counterparty | Date + Headline Value | Structure + Assets |
|---|---|---|
| Eccogene (AZD5004 + Greater China rights retained) | November 2023; up to ~$2B | $185M upfront cash + $1.825B in milestone payments (development + regulatory + commercial) + royalty on commercial sales (mid-single-digit to low-teens range estimated). AZN took global rights ex-China; Eccogene retains Greater China. Asset acquired: AZD5004 (formerly ECC5004) oral small-molecule GLP-1 receptor agonist |
| AZD6234 internal development | Disclosed publicly Q3 2024; no external deal | Internal AstraZeneca asset originating from in-house research; no licensing or acquisition transaction; long-acting injectable amylin receptor agonist; positioning for combination with AZD5004; advancing through Phase 1 + early Phase 2 |
| Sciwind ecnoglutide partnership | Status: not AZN; Pfizer counterpart | Sciwind's ecnoglutide (an injectable cAMP-biased GLP-1) is partnered with Pfizer China for Mainland China commercialization (announced February 2026, up to $495M), not AZN; included here only for clarification |
| Cumulative obesity in-licensing commitment | 2023-2025 | AZN's total obesity in-licensing commitment is ~$185M upfront cash + ~$1.825B in contingent milestones + royalty obligations + ongoing internal AZD6234 development costs. Total upfront + near-term-cash exposure: ~$200-300M. Significantly lower than Roche (~$2.7B Carmot + ~$1.65B Zealand petrelintide upfront) or Pfizer (~$7.0B upfront for Metsera, up to ~$10B with the CVR) |
| Other potential acquirees evaluated | Industry speculation | Analyst and trade-press commentary suggested AstraZeneca weighed multiple obesity assets during 2023-2025 before choosing to license (Eccogene) and develop internally (AZD6234) rather than pursue a large acquisition; specific targets are not company-confirmed |
| Editorial. Why this matters | Strategic context | AZN's combination strategy (oral GLP-1 + oral amylin) is differentiated but back-end-loaded: most of the deal value sits in milestones tied to Phase 3 + regulatory + commercial outcomes. If AZD5004 + AZD6234 combination produces synergistic Phase 3 data, AZN wins with minimal cash deployment. If the combination underperforms, AZN's contingent milestones are not triggered and the company has spent <$300M to participate in the category. The strategic question: was AZN's discipline + asset-selection correct, or did the company under-invest in a category where speed-to-launch matters more than capital efficiency? |
2019-Q2-2023-Q2
2010-2025
$AZN
AZD6234 (oral amylin agonist, APRICUS Phase 2b completing 2026) and ECC5004 (oral GLP-1). Building a credible third-tier biopharma franchise behind Lilly and Novo.